Spyre Therapeutics Grants Inducement Awards

Spyre Therapeutics, a clinical-stage biotechnology company, announced two separate grants of equity inducement awards to non-executive employees. On June 1, 2026, the company's Compensation Committee approved the grant of stock options to four employees to purchase 51,300 shares of common stock at an exercise price of $70.54. On July 1, 2026, the committee approved grants to six employees for 58,843 shares of common stock and 2,134 restricted stock units (RSUs) at an exercise price of $88.89. These awards, granted under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, are considered material to the employees' acceptance of employment and are subject to vesting schedules based on continuous service.